Outcome of COVID19 in Patients With Osteogenesis Imperfecta: A Retrospective Multicenter Study in Saudi Arabia

Alshukairi, Abeer N.; Doar, Hazem; Alsagheir, Afaf; Bahasan, Mona; Sultan, Abdul H.; Hroub, Mohammad K Al; Itani, Dina; Khalid, Imran; Saeedi, Mohammed F.; Bakhamis, Sarah; Layqah, Laila; Almutairi, Afnan A.; Saifullah, Mona; Hefni, Lama; Al‐Omari, Awad; Alraddadi, Basem; Baharoon, Salim

doi:10.3389/fendo.2021.800376

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a need for countries to address the unmet need for investment in prevention of illness for those with rare diseases via clinical research and development activities ( 29 ). It is reassuring however that evidence to date shows that COVID-19 infection does not have a particularly adverse effect on those with OI ( 30 ). During the pandemic, the BBS provided online COVID-19 information to its members, with the majority of respondents finding this very helpful.…”

Section: Discussionmentioning

confidence: 99%

Patient-reported experience of clinical care of osteogenesis imperfecta (OI) during the COVID-19 pandemic

Smyth

Hytiris

Kelday

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

BackgroundResearch on the effects of the COVID-19 pandemic on people with rare diseases is limited. Few studies compare healthcare throughout the progression of the ongoing pandemic.AimsTo assess the impact of the pandemic on individuals with osteogenesis imperfecta across two consecutive years, understand what challenges were encountered, and analyse the experience of remote consultation.MethodsAn initial survey was distributed following the first lockdown in August 2020, and a second survey in April 2021. The surveys explored four themes- effects on therapy, alternatives to consultation, effect on mental health, and perceived risks of COVID-19.ResultsIn the 2020 survey, of the 110 respondents, 69 (63%) had at least one appointment delayed due to the lockdown, compared with 89 of the 124 respondents (72%) in 2021. Of the 110 respondents in 2020, 57 (52%) had a remote consultation, increasing to 92 of 124 (74%) in the follow-up survey. In the 2020 survey 63 of 91 respondents (69%) expressed anxiety due to lockdown, compared with 76 of 124 (61%) in 2021. The percentage of total respondents expressing a preference for remote consultation was 48% in 2020, increasing to 71% in 2021.ConclusionsThe pandemic has had widespread effects on the mental and physical health of those with OI. These effects, alongside appointment delays, have increased as the pandemic progresses. Encouragingly, the increasing preference for remote consultation may indicate that this could be a viable long-lasting alternative to face-to-face appointments, especially for patients who previously traveled vast distances for specialist care.

show abstract

Section: Discussionmentioning

confidence: 99%

Patient-reported experience of clinical care of osteogenesis imperfecta (OI) during the COVID-19 pandemic

Smyth

Hytiris

Kelday

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Additionally, patients with COL1A1+COL1A2 gene mutations have shown various forms of cardiovascular pathology, particularly regurgitation of the heart valves, attributed to poor collagen [ 119 ]. Interestingly, a small study examining pediatric OI patients found that they had no difference in outcome after COVID-19 infection [ 120 ]. Moreover, two therapies used for OI, mesenchymal stem cells and decidua stromal cells were used to treat SARS-CoV-2 coronavirus-induced disease [ 121 ] as an anti-inflammatory treatment to reduce COVID-induced cytokine storm.…”

Section: Discussionmentioning

confidence: 99%

Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19

Kartchner,

McCoy,

Dubey

et al. 2023

Biology

View full text Add to dashboard Cite

Multiple studies have reported new or exacerbated persistent or resistant hypertension in patients previously infected with COVID-19. We used literature-based discovery to identify and prioritize multi-scalar explanatory biology that relates resistant hypertension to COVID-19. Cross-domain text mining of 33+ million PubMed articles within a comprehensive knowledge graph was performed using SemNet 2.0. Unsupervised rank aggregation determined which concepts were most relevant utilizing the normalized HeteSim score. A series of simulations identified concepts directly related to COVID-19 and resistant hypertension or connected via one of three renin–angiotensin–aldosterone system hub nodes (mineralocorticoid receptor, epithelial sodium channel, angiotensin I receptor). The top-ranking concepts relating COVID-19 to resistant hypertension included: cGMP-dependent protein kinase II, MAP3K1, haspin, ral guanine nucleotide exchange factor, N-(3-Oxododecanoyl)-L-homoserine lactone, aspartic endopeptidases, metabotropic glutamate receptors, choline-phosphate cytidylyltransferase, protein tyrosine phosphatase, tat genes, MAP3K10, uridine kinase, dicer enzyme, CMD1B, USP17L2, FLNA, exportin 5, somatotropin releasing hormone, beta-melanocyte stimulating hormone, pegylated leptin, beta-lipoprotein, corticotropin, growth hormone-releasing peptide 2, pro-opiomelanocortin, alpha-melanocyte stimulating hormone, prolactin, thyroid hormone, poly-beta-hydroxybutyrate depolymerase, CR 1392, BCR-ABL fusion gene, high density lipoprotein sphingomyelin, pregnancy-associated murine protein 1, recQ4 helicase, immunoglobulin heavy chain variable domain, aglycotransferrin, host cell factor C1, ATP6V0D1, imipramine demethylase, TRIM40, H3C2 gene, COL1A1+COL1A2 gene, QARS gene, VPS54, TPM2, MPST, EXOSC2, ribosomal protein S10, TAP-144, gonadotropins, human gonadotropin releasing hormone 1, beta-lipotropin, octreotide, salmon calcitonin, des-n-octanoyl ghrelin, liraglutide, gastrins. Concepts were mapped to six physiological themes: altered endocrine function, 23.1%; inflammation or cytokine storm, 21.3%; lipid metabolism and atherosclerosis, 17.6%; sympathetic input to blood pressure regulation, 16.7%; altered entry of COVID-19 virus, 14.8%; and unknown, 6.5%.

show abstract

“…In a study by Alshukairi et al, children with osteogenesis imperfecta and COVID-19 exhibited a mild course of the disease and recovered without complications [110]. Children with metabolic bone disease or a skeletal dysplasia that affect chest wall structure and respiratory sufficiency may be at increased risk of COVID-19 complications [111].…”

Section: Metabolic Bone Diseasementioning

confidence: 99%

The Interplay Between COVID-19 and Pediatric Endocrine Disorders. What have we Learned After More than Three Years of the Pandemic?

Kostopoulou

2023

Horm Metab Res

View full text Add to dashboard Cite

As an increased body of COVID-19 related research is now available, it becomes apparent that the effects of COVID-19 extend beyond that of the respiratory system. Among others, the endocrine system is particularly vulnerable to perturbation from the COVID-19 infection. The present scoping review summarizes the bidirectional relationship between COVID-19 and endocrine system in children and adolescents, by describing both the possible susceptibility of children and adolescents without endocrinopathies to endocrine disorders following COVID-19 infection, but also the potential susceptibility to COVID-19 infection and severe infection, or the aggravation of endocrine dysfunction in patients with pre-existing endocrine diseases. Data suggest increased obesity and diabetes rates, as well as increased severity and frequency of diabetic ketoacidosis following COVID-19 infection. Conversely, patients with diabetes and obesity may experience a more severe course of COVID-19 infection. However, in the majority of cases, children and adolescents with well-managed and regulated endocrine disorders do not appear to be at increased risk of infection or severe infection from COVID-19. Thus, adhering to the appropriate “sick day management rules”, maintaining adequate supply of medications and supplies, keeping close contact with the therapeutic team and seeking medical help without delay when needed, are the main recommendations for a safe outcome. Additional lessons learnt during the pandemic include the risk for mental health diseases caused by children’s disrupted routine due to COVID-19 related protective measures and the importance of adopting alternative communication options, such as telehealth visits, in order to ensure uninterrupted endocrine care.

show abstract

Outcome of COVID19 in Patients With Osteogenesis Imperfecta: A Retrospective Multicenter Study in Saudi Arabia

Cited by 4 publications

References 29 publications

Patient-reported experience of clinical care of osteogenesis imperfecta (OI) during the COVID-19 pandemic

Patient-reported experience of clinical care of osteogenesis imperfecta (OI) during the COVID-19 pandemic

Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19

The Interplay Between COVID-19 and Pediatric Endocrine Disorders. What have we Learned After More than Three Years of the Pandemic?

Contact Info

Product

Resources

About